Clinical trial
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in…
NCT00282230 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00282230 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients |
| Official title | A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Transplantation |
| Intervention type | Drug |
| Interventions | FK778 |
| Enrollment | 150 |
| Start date | Nov 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Jan 26, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: